441 related articles for article (PubMed ID: 20667129)
1. Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity.
Gunn S; Yeh IT; Lytvak I; Tirtorahardjo B; Dzidic N; Zadeh S; Kim J; McCaskill C; Lim L; Gorre M; Mohammed M
BMC Cancer; 2010 Jul; 10():396. PubMed ID: 20667129
[TBL] [Abstract][Full Text] [Related]
2. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of HER2 gene status in breast cancer with HER2 protein overexpression].
Zeng X; Liang ZY; Wu SF; Zhou WX; Gao J; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):584-8. PubMed ID: 17134563
[TBL] [Abstract][Full Text] [Related]
4. Global search for chromosomal abnormalities in infiltrating ductal carcinoma of the breast using array-comparative genomic hybridization.
Somiari SB; Shriver CD; He J; Parikh K; Jordan R; Hooke J; Hu H; Deyarmin B; Lubert S; Malicki L; Heckman C; Somiari RI
Cancer Genet Cytogenet; 2004 Dec; 155(2):108-18. PubMed ID: 15571796
[TBL] [Abstract][Full Text] [Related]
5. Genomic Copy Number Analysis of HER2-Equivocal Breast Cancers.
Geiersbach KB; Willmore-Payne C; Pasi AV; Paxton CN; Werner TL; Xu X; Wittwer CT; Gulbahce HE; Downs-Kelly E
Am J Clin Pathol; 2016 Oct; 146(4):439-47. PubMed ID: 27614666
[TBL] [Abstract][Full Text] [Related]
6. Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer.
Varga Z; Tubbs RR; Wang Z; Sun Y; Noske A; Kradolfer D; Bosshard G; Jochum W; Moch H; Öhlschlegel C
Breast Cancer Res Treat; 2012 Apr; 132(3):925-35. PubMed ID: 21698407
[TBL] [Abstract][Full Text] [Related]
7. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis.
Marchiò C; Lambros MB; Gugliotta P; Di Cantogno LV; Botta C; Pasini B; Tan DS; Mackay A; Fenwick K; Tamber N; Bussolati G; Ashworth A; Reis-Filho JS; Sapino A
J Pathol; 2009 Sep; 219(1):16-24. PubMed ID: 19670217
[TBL] [Abstract][Full Text] [Related]
8. Assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number.
Jang MH; Kim EJ; Kim HJ; Chung YR; Park SY
Breast Cancer Res Treat; 2015 Aug; 153(1):67-77. PubMed ID: 26223814
[TBL] [Abstract][Full Text] [Related]
9. HER2 FISH results in breast cancers with increased CEN17 signals using alternative chromosome 17 probes - reclassifying cases in the equivocal category.
Holzschuh MA; Czyz Z; Hauke S; Inwald EC; Polzer B; Brockhoff G
Histopathology; 2017 Oct; 71(4):610-625. PubMed ID: 28502100
[TBL] [Abstract][Full Text] [Related]
10. [Comparison between analysis of HER2 gene and chromosome 17 in breast cancer by dual-probe chromogenic in situ hybridization and fluorescence in situ hybridization].
Bai YF; Ren GP; Wang B; Teng LS; Liu X
Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):161-5. PubMed ID: 20450761
[TBL] [Abstract][Full Text] [Related]
11. Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event.
Yeh IT; Martin MA; Robetorye RS; Bolla AR; McCaskill C; Shah RK; Gorre ME; Mohammed MS; Gunn SR
Mod Pathol; 2009 Sep; 22(9):1169-75. PubMed ID: 19448591
[TBL] [Abstract][Full Text] [Related]
12. Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines.
Press MF; Seoane JA; Curtis C; Quinaux E; Guzman R; Sauter G; Eiermann W; Mackey JR; Robert N; Pienkowski T; Crown J; Martin M; Valero V; Bee V; Ma Y; Villalobos I; Slamon DJ
JAMA Oncol; 2019 Mar; 5(3):366-375. PubMed ID: 30520947
[TBL] [Abstract][Full Text] [Related]
13. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
Donaldson AR; Shetty S; Wang Z; Rivera CL; Portier BP; Budd GT; Downs-Kelly E; Lanigan CP; Calhoun BC
Cancer; 2017 Jun; 123(12):2230-2239. PubMed ID: 28192599
[TBL] [Abstract][Full Text] [Related]
14. Fluorescence in situ hybridization of chromosome 17 polysomy in breast cancer using thin tissue sections causes the loss of CEP17 and HER2 signals.
Jiang H; Bai X; Zhao T; Zhang C; Zhang X
Oncol Rep; 2014 Nov; 32(5):1889-96. PubMed ID: 25119636
[TBL] [Abstract][Full Text] [Related]
15. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
[TBL] [Abstract][Full Text] [Related]
16. Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy.
Tse CH; Hwang HC; Goldstein LC; Kandalaft PL; Wiley JC; Kussick SJ; Gown AM
J Clin Oncol; 2011 Nov; 29(31):4168-74. PubMed ID: 21947821
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study.
Sneige N; Hess KR; Multani AS; Gong Y; Ibrahim NK
Cancer; 2017 Apr; 123(7):1115-1123. PubMed ID: 27893937
[TBL] [Abstract][Full Text] [Related]
18. HER2 expression in breast cancer with nonamplified HER2 and gains of chromosome 17 centromere.
Panvichian R; Tantiwetrueangdet A; Wongwaisayawan S; Nampoon A; Lertsithichai P; Leelaudomlipi S
Appl Immunohistochem Mol Morphol; 2012 Jul; 20(4):367-74. PubMed ID: 22417858
[TBL] [Abstract][Full Text] [Related]
19. Impact of 2013 ASCO/CAP guidelines on HER2 determination of invasive breast cancer: A single institution experience using frontline dual-color FISH.
Ragazzi M; Bisagni A; Gasparini E; Kuhn E; Bassano C; Tamagnini I; Foroni M; Bortesi M; Falco G; Ferrari G; Braglia L; Savoldi L; Bologna A; Di Cicilia R; Bisagni G; Gardini G
Breast; 2017 Aug; 34():65-72. PubMed ID: 28521178
[TBL] [Abstract][Full Text] [Related]
20. Utility of Alternate, Noncentromeric Chromosome 17 Reference Probe for Human Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization Testing in Breast Cancer Cases.
Pai T; Shet T; Patil A; Shetty O; Singh A; Desai SB
Arch Pathol Lab Med; 2018 May; 142(5):626-633. PubMed ID: 29384691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
